Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20722167 | 1.00 | S1PR1 (0.37) | S1PR1DDB1CRBNMGLLCYP3A4 | |
| SCHEMBL20722200 | 1.00 | S1PR1 (0.37) | S1PR1DDB1CRBNMGLLCYP3A4 | |
| SCHEMBL20739606 | 0.83 | HPGD (0.51) | SMN1; SMN2 | |
| SCHEMBL20739480 | 0.83 | S1PR1 (0.44) | S1PR1KDM1AITGB3ITGA2BCYP2D6 | |
| SCHEMBL20722178 | 0.83 | HPGD (0.51) | SMN1; SMN2 | |
| SCHEMBL28291397 | 0.81 | BLM (0.41) | CYP3A4CYP2C9HSD17B10ALDH1A1GAA | |
| SCHEMBL23384545 | 0.81 | S1PR1 (0.42) | S1PR1GAAKDM1AITGB3ITGA2B | |
| SCHEMBL20722161 | 0.80 | ITGB3 (0.40) | S1PR1CYP3A4CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL23384541 | 0.79 | S1PR1 (0.41) | S1PR1GAAKDM1AITGB3ITGA2B | |
| SCHEMBL23384542 | 0.78 | ITGB3 (0.42) | S1PR1MGLLCYP3A4SMN1; SMN2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059784-B2 | Oxime ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210147361-A1 | OXIME ETHER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147361-A1 | OXIME ETHER COMPOUNDS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885DDB1 2565/4885CRBN 717/4885 |
| US-11059784-B2 | Oxime ether compounds | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885DDB1 2698/4885CRBN 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.